Accelerate your oncology R&D with quality biospecimens & data

Our biospecimen repository is purpose-built to accelerate oncology therapeutic development.

We are a key resource for

Pharma & biotech

Reliable & robust assay performance starts with high quality specimens. Our ethically approved anonymized clinical samples include annotated histopathological and molecular data plus clinical follow-up information.

Diagnostics companies

Our specimens and control tissues make us a key resource for diagnostic companies specializing in either histologic or nucleic acid assays, NGS, multiplex assays, and IHC using all prevalent platforms.

AI companies

TriStar offers a large searchable library of digital images including H&E and IHC stained tissues and associated metadata for use in algorithm development.


Multi-spectral spatial analysis of pre-treatment NSCLC cohort with 2nd line immunotherapy response data using MOTiFTM lung cancer PD-1/PD-L1 panel (Akoya).

Representative analysis of TMA cores from responders to immune checkpoint inhibitors (ICI; top row) and non-responders (lower row). Volcano plot indicates enrichment & significance of cellular interactions - for example, between CD68+ and PD-1+/FoxP3+ cells in ICI-refractory tumors. Such studies can provide early insights into predictive biomarkers associated with response to ICI.

An expansive collection of unique tissue microarrays with extensive follow-up & molecular data

Scientifically relevant TMAs for your biomarker research developed from our strategically collected human tissue samples & collaborations

FFPE blocks, TMAs, Double-Spun Plasma, Buffy Coat

Multi Tumor, Normal, Tumor-specific and Variant-specific TMAs

Follow Up Data including Treatment, Response, Survival Information, and Molecular Data (IHC, NGS & RNAseq)

RNAscope pre-qualified TMAs, TMAs with NGS, RNAseq data

High quality tissues deliver high quality research

Our samples are well-suited to IHC, RNA-ISH, and NGS platforms.

FFPE blocks

We collaborate with Western Europe & the UK’s leading medical centers for samples of consistent quality which include follow up data on chemotherapy targeted and immuno-oncology treatments.

Double Spun Plasma

Explore circulating non-invasive biomarkers with double spun plasma matched to FFPE samples.

Integrated biomarker services – samples, annotated clinical & molecular data combined with expert CRO capabilities.

TriStar offers integrated biomarker services complete with samples, annotated clinical & molecular data and expert CRO capabilities

IHC Services

Our experienced ex-pharma scientists & pathologists specialize in IHC assay development, and protocol optimization & analysis to deliver robust data while accelerating project decisions.


RNAScope services offered with standard & custom probes plus pathology expertise and scoring per ACD guidelines.

NGS Services

Samples annotated using standard ThermoFisher & Illumina panels, Genexus & NovaSeq equipment. Reports can include TMB, HLA-DR, MSI, TCR and BCR.

Digital Spatial Profiling

Analyze targets & spatial relationships in context of TME with CODEX & Nanostring GeoMx DSP.

Image Analysis

Quantify and localize target expression across tumor types.

Prevalence Studies

TriStar’s services can be used to guide patient selection for projects & inform the path to clinical development. TMAs and/or FFPE blocks can be combined into sets to screen 150-1500 donor samples per indication.


Extensive collection of specimens reviewed and approved by pathologists for use in immuno-oncology assays.

Targeted Cancer Therapeutics

Explore oncology target expression, resistance mechanisms & cancer pathway interactions in specimens with NGS data & mutation status.

Antibody-Drug Conjugates (ADCs)

TMAs and FFPE blocks with ADC relevant target expression information, treatment and follow up data

An industry-experienced scientific team to work with you to customize a fit-for-purpose biospecimen, data, and/or integrated services solution

Our approach begins with our customers’ science.

We focus our acquisition on patient cohorts that meet the needs of biopharma, clinical, and translational researchers.


Featured Resources





Tumor heterogeneity and primary versus metastatic evaluation of PD-L1


Multidimensional Gene Expression Models for Characterizing Response...